Regulatory and compounding status All four compounds share a broadly similar regulatory landscape in the United States as of 2026: None are FDA-approved as finished drug products for therapeutic use All are classified as WADA S2 prohibited substances year-round All four have 503A compounding status of Under Review, meaning the FDA Pharmacy Compounding Advisory Committee (PCAC) has nominated them for evaluation but final category assignments (Category 1 permitted for compounding
What causes the weight loss to plateau, and what happens when you quit the drugs
Research shows that results after stopping GLP-1 medications varysome people can maintain their weight loss, while others benefit from ongoing treatment, often at a lower or intermittent dose
GLP-1 medications are a class of prescription drugs known as glucagon-like peptide-1 receptor agonists
Adult growth hormone deficiency benefits, side effects, and risks of growth hormone replacement
Clinical trials demonstrate that most weight reduction occurs over the first six months of treatment, with continued but slower loss thereafter